Sumitomo Pharmaceuticals, also known as Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company based in Japan. The company was formed in 2005 through a merger between Sumitomo Pharmaceuticals and Dainippon Pharmaceuticals.
Sumitomo Dainippon Pharma focuses on research, development, manufacturing, and marketing of pharmaceutical products in various therapeutic areas, including central nervous system disorders, oncology, diabetes, and cardiovascular diseases.
The company has a global presence, with operations in Japan, the United States, Europe, and other regions. Sumitomo Dainippon Pharma is committed to improving the lives of patients by developing innovative and effective treatments for various medical conditions.
Some of the key products developed by Sumitomo Dainippon Pharma include Latuda (lurasidone) for the treatment of schizophrenia and bipolar depression, Gocovri (amantadine) for Parkinson's disease, and Lonsurf (trifluridine/tipiracil) for colorectal cancer.
Overall, Sumitomo Dainippon Pharma is a leading pharmaceutical company known for its commitment to research and development, innovation, and providing high-quality healthcare products to patients worldwide.
Ne Demek sitesindeki bilgiler kullanıcılar vasıtasıyla veya otomatik oluşturulmuştur. Buradaki bilgilerin doğru olduğu garanti edilmez. Düzeltilmesi gereken bilgi olduğunu düşünüyorsanız bizimle iletişime geçiniz. Her türlü görüş, destek ve önerileriniz için iletisim@nedemek.page